Radiopharmaceutical Theranostics Market Worth $3.44 Billion, Globally, by 2028 at 11.3% CAGR | The Insight Partners
March 29, 2023 10:15 ET
|
The Insight Partners
Pune, India, March 29, 2023 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Radiopharmaceutical Theranostics Market Size, Share, Revenue, Growth Strategy, Industry...
POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
March 27, 2023 08:00 ET
|
POINT Biopharma
Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH...
ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma
March 13, 2023 06:13 ET
|
ITM Isotope Technologies Munich SE
Garching/Munich, Munich and Münster, Germany, March 13, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, Helmholtz Munich and the Departments of...
Global Nuclear Medicine Imaging Equipment Strategic Report 2023: PET-MRI Emerging as a Promising Standard for Imaging Soft Tissue Contrast
March 07, 2023 12:13 ET
|
Research and Markets
Dublin, March 07, 2023 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Imaging Equipment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
March 07, 2023 07:45 ET
|
POINT Biopharma
INDIANAPOLIS, March 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma to Participate in Upcoming Investor Conferences
February 02, 2023 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
January 12, 2023 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 10:30 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, January 03, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will...
POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy
November 29, 2022 07:30 ET
|
POINT Biopharma
Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model ...
Outlook on the Nuclear Medicine Global Market to 2028: Use of Radiopharmaceuticals in Neurological Applications Presents Opportunities
November 16, 2022 04:08 ET
|
Research and Markets
Dublin, Nov. 16, 2022 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028" report has been added to ResearchAndMarkets.com's...